CN104770740A - Haematococcus pluvialis and astaxanthin compound preparation - Google Patents
Haematococcus pluvialis and astaxanthin compound preparation Download PDFInfo
- Publication number
- CN104770740A CN104770740A CN201510220212.5A CN201510220212A CN104770740A CN 104770740 A CN104770740 A CN 104770740A CN 201510220212 A CN201510220212 A CN 201510220212A CN 104770740 A CN104770740 A CN 104770740A
- Authority
- CN
- China
- Prior art keywords
- haematococcus pluvialis
- powder
- astaxanthin
- parts
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a haematococcus pluvialis and astaxanthin compound preparation. The haematococcus pluvialis and astaxanthin compound preparation comprises, by weight, 15-20 parts of haematococcus pluvialis powder, 2-4 parts of lycopene, 2-5 parts of grape seed extracts, 1-3 parts of green tea extracts, 1-2 parts of blueberry extracts, 0.5-1 part of hippophae rhamnoides extracts, 0.5-1 part of hawthorn extracts, 0.4-0.8 part of golden mushroom extracts, 0.2-0.4 part of mangosteen extracts, 1-2 parts of soybean protein powder, 0.3-0.6 part of water-soluble pearl powder, 0.2-0.5 part of walnut powder, 0.2-0.4 part of oat powder, 0.05-0.1 part of salmon roe powder, 0.02-0.8 part of se-enriched yeast, 0.3-0.6 part of vitamin E and 0.2-0.4 part of vitamin C. The ratio of raw materials selected for the haematococcus pluvialis and astaxanthin compound preparation is scientific and reasonable, and human feeding trials show that the haematococcus pluvialis and astaxanthin compound preparation has the good functions of resisting oxidation and scavenging free radicals.
Description
Technical field
The present invention relates to a kind of health food preparation of oxidation and removing free radicals, especially a kind of Astaxanthin In Haematococcus Pluvialis compound formulation.
Background technology
Free radical is the hazardous compound produced in body oxidation reaction, has strong oxidizing property, can damage tissue and the cell of body, and then cause chronic disease and aging effect.
Numerous medical research and clinical testing prove: human body cell electronics is the source of ten thousand diseases by plunder, free radical is exactly a kind of material lacking electronics, electronics is fought for everywhere after entering human body, if seize the electronics of cell protein molecule, make protein connect side chain generation alkylation, formed distortion molecule and carcinogenic.This distortion molecule lacks electronics due to oneself, removes the electronics capturing neighboring molecule again, make again neighboring molecule also occur distortion and carcinogenic.Like this, vicious circle will form the protein molecular of a large amount of distortion.Gene mutation, forms a large amount of cancer cell, finally occurs cancer.And when free radical or distortion molecule have grabbed the electronics of gene, people directly will obtain cancer.
Summary of the invention
The invention provides a kind of Astaxanthin In Haematococcus Pluvialis compound formulation, can be used for anti-oxidant, scavenging free radicals.
The present invention realizes with following technical scheme: a kind of Astaxanthin In Haematococcus Pluvialis compound formulation, it is characterized in that it is made up of the common hybrid process of the raw material of following portions by weight: haematococcus pluvialis powder 15-20 part, lycopene 2-4 part, grape seed extract 2-5 part, green-tea extract 1-3 part, blueberry extract 1-2 part, hippophae rhamnoides 0.5-1 part, haw thorn extract 0.5-1 part, gold needle mushroom extract 0.4-0.8 part, mangosteen extract 0.2-0.4 part, soyabean protein powder 1-2 part, water soluble pearl powder 0.3-0.6 part, walnut powder 0.2-0.5 part, oatmeal 0.2-0.4 part, salmon roe powder 0.05-0.1 part, Se-enriched yeast 0.02-0.08 part, vitamin E 0.3-0.6 part, vitamin C 0.2-0.4 part.
The Determination of Astaxanthin in Haematococcus Pluvialis content that the present invention adopts is greater than 2%.
The present invention also discloses a kind of granule, tablet, hard capsule, soft capsule, pulvis, adds auxiliary material obtain through corresponding technique by aforementioned base materials.
Haematococcus pluvialis is called again the raw haematococcus in lake or lake green blood ball algae, is a kind of ubiquitous green alga, belongs to volvocales, haematococcus section.Haematococcus pluvialis is acknowledged as the best biology that occurring in nature produces natural astaxanthin.Determination of Astaxanthin in Haematococcus Pluvialis content is 1.5% ~ 3.0%, is counted as " concentrate " of natural astaxanthin.
Natural astaxanthin is that the mankind find the antioxidant that nature is the strongest, and its antioxidation activity exceedes existing antioxidant.The ability of its scavenging free radicals is 6000 times of ascorbic effect; It is 1000 times of vitamin E; It is 700 times of anthocyanidin; It is 100 times of beta carotene effect.
The invention has the beneficial effects as follows: the present invention adopts pure natural plant raw material, filling a prescription studies science in strict accordance with theory of traditional Chinese medical science and modern health drafts, whole reasonable recipe, rigorous, the health food of multiple formulation can be prepared into, raw material is easy to get, and preparation technology is relatively simple, and cost can be controlled.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described further.
Embodiment 1
A kind of Astaxanthin In Haematococcus Pluvialis compound formulation, this health food is prepared into hard shell capsules, its component and parts by weight are: haematococcus pluvialis powder (content astaxanthin 2.5%) 16 parts, lycopene 3 parts, grape seed extract 4 parts, green-tea extract 1 part, blueberry extract 2 parts, hippophae rhamnoides 0.6 part, haw thorn extract 0.8 part, gold needle mushroom extract 0.4 part, mangosteen extract 0.3 part, soyabean protein powder 2 parts, water soluble pearl powder 0.4 part, walnut powder 0.4 part, oatmeal 0.2 part, 0.07 part, salmon roe powder, Se-enriched yeast 0.04 part, vitamin E 0.5 part, vitamin C 0.2 part.Above-mentioned raw materials is mixed, is filled in capsule shells by hard shell capsules automatic filling equipment, makes hard capsule.
According to Example formulations, 1000 people try out, and wherein 935 people think that the present invention has significant effect in anti-oxidant, scavenging free radicals, and satisfaction rate is up to 93.5%.
Embodiment 2
A kind of Astaxanthin In Haematococcus Pluvialis compound formulation, this health food is prepared into tablet, its component and parts by weight are: haematococcus pluvialis powder (content astaxanthin 2.3%) 19 parts, lycopene 2 parts, grape seed extract 3 parts, green-tea extract 2 parts, blueberry extract 1 part, hippophae rhamnoides 0.8 part, haw thorn extract 0.6 part, gold needle mushroom extract 0.7 part, mangosteen extract 0.2 part, soyabean protein powder 1 part, water soluble pearl powder 0.5 part, walnut powder 0.3 part, oatmeal 0.4 part, 0.08 part, salmon roe powder, Se-enriched yeast 0.06 part, vitamin E 0.4 part, vitamin C 0.3 part.Above-mentioned raw materials is added a certain amount of sodium carboxymethyl starch, after granulation, is pressed into plain sheet, dressing, obtains tablet.
According to Example formulations, 1000 people try out, and wherein 941 people think that the present invention has significant effect in anti-oxidant, scavenging free radicals, and satisfaction rate is up to 94.1%.
Above to invention has been detailed introduction, the explanation of above embodiment just understands the present invention for helping.Those of ordinary skill in the art should be appreciated that to change technical scheme of the present invention, retouch or be equal to and replaces, and does not depart from the spirit and scope of technical solution of the present invention, and it all should belong in the middle of claims of the present invention.
Claims (3)
1. an Astaxanthin In Haematococcus Pluvialis compound formulation, it is characterized in that it is made up of the common hybrid process of the raw material of following portions by weight: haematococcus pluvialis powder 15-20 part, lycopene 2-4 part, grape seed extract 2-5 part, green-tea extract 1-3 part, blueberry extract 1-2 part, hippophae rhamnoides 0.5-1 part, haw thorn extract 0.5-1 part, gold needle mushroom extract 0.4-0.8 part, mangosteen extract 0.2-0.4 part, soyabean protein powder 1-2 part, water soluble pearl powder 0.3-0.6 part, walnut powder 0.2-0.5 part, oatmeal 0.2-0.4 part, salmon roe powder 0.05-0.1 part, Se-enriched yeast 0.02-0.08 part, vitamin E 0.3-0.6 part, vitamin C 0.2-0.4 part.
2. an Astaxanthin In Haematococcus Pluvialis compound formulation, is characterized in that, according to claim 1, Determination of Astaxanthin in Haematococcus Pluvialis content is greater than 2%.
3. an Astaxanthin In Haematococcus Pluvialis compound formulation, is characterized in that, the raw material of claim 1 adds auxiliary material through obtained granule, tablet, hard capsule, soft capsule, the pulvis of corresponding technique.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510220212.5A CN104770740A (en) | 2015-05-04 | 2015-05-04 | Haematococcus pluvialis and astaxanthin compound preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510220212.5A CN104770740A (en) | 2015-05-04 | 2015-05-04 | Haematococcus pluvialis and astaxanthin compound preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104770740A true CN104770740A (en) | 2015-07-15 |
Family
ID=53612760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510220212.5A Pending CN104770740A (en) | 2015-05-04 | 2015-05-04 | Haematococcus pluvialis and astaxanthin compound preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104770740A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105394749A (en) * | 2015-10-23 | 2016-03-16 | 武汉龙族药号生物医药科技有限公司 | Formula, preparation method and application of astaxanthin-containing health food |
| CN105454733A (en) * | 2015-12-31 | 2016-04-06 | 中国科学院海洋研究所 | Rainbow trout nutrition enhancer and application thereof |
| CN106722434A (en) * | 2015-11-19 | 2017-05-31 | 徐州统食品工业有限公司 | A kind of anti-oxidation functional food |
| CN106721918A (en) * | 2016-11-24 | 2017-05-31 | 云南民族大学 | Astaxanthin green tea oral tablet |
| CN107441236A (en) * | 2017-06-02 | 2017-12-08 | 杭州鑫伟低碳技术研发有限公司 | A kind of Astaxanthin In Haematococcus Pluvialis liver protecting product and preparation method thereof |
| CN108902958A (en) * | 2018-07-20 | 2018-11-30 | 深圳市博奥生物科技有限公司 | A kind of astaxanthin soft capsule and preparation method thereof |
| CN109430833A (en) * | 2018-10-31 | 2019-03-08 | 杭州鑫伟低碳技术研发有限公司 | A kind of composition and its application for improving reproduction cell vigor |
| CN110754659A (en) * | 2019-11-12 | 2020-02-07 | 青岛浩然海洋科技有限公司 | Production method of astaxanthin oral liquid |
| CN110839881A (en) * | 2019-11-26 | 2020-02-28 | 康道生物（南通）有限公司 | Ganoderma lucidum spore oil lycopene soft capsule and preparation process thereof |
| CN111363658A (en) * | 2020-03-05 | 2020-07-03 | 何凤霞 | A beverage containing Haematococcus pluvialis extract (astaxanthin) and its preparation method |
| CN112890133A (en) * | 2021-03-24 | 2021-06-04 | 康道生物（南通）有限公司 | Preparation process of haematococcus pluvialis capsules |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890056A (en) * | 2010-08-05 | 2010-11-24 | 郭景龙 | Medicinal composition for enhancing immunologic function |
| CN103271258A (en) * | 2013-05-15 | 2013-09-04 | 上海莱博生物科技有限公司 | Health product and application thereof |
| CN103431401A (en) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | Antioxidant health care food and application thereof |
| CN103689090A (en) * | 2014-01-03 | 2014-04-02 | 宋信宇 | Milk beverage formula containing algae |
| CN104055122A (en) * | 2014-07-09 | 2014-09-24 | 江西维莱营健高科有限公司 | Haematococcus pluvialis and blueberry extract soft capsules and preparation method thereof |
| CN104431860A (en) * | 2014-12-31 | 2015-03-25 | 陈智辉 | Health-care food with senescence delaying function |
-
2015
- 2015-05-04 CN CN201510220212.5A patent/CN104770740A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890056A (en) * | 2010-08-05 | 2010-11-24 | 郭景龙 | Medicinal composition for enhancing immunologic function |
| CN103271258A (en) * | 2013-05-15 | 2013-09-04 | 上海莱博生物科技有限公司 | Health product and application thereof |
| CN103431401A (en) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | Antioxidant health care food and application thereof |
| CN103689090A (en) * | 2014-01-03 | 2014-04-02 | 宋信宇 | Milk beverage formula containing algae |
| CN104055122A (en) * | 2014-07-09 | 2014-09-24 | 江西维莱营健高科有限公司 | Haematococcus pluvialis and blueberry extract soft capsules and preparation method thereof |
| CN104431860A (en) * | 2014-12-31 | 2015-03-25 | 陈智辉 | Health-care food with senescence delaying function |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105394749A (en) * | 2015-10-23 | 2016-03-16 | 武汉龙族药号生物医药科技有限公司 | Formula, preparation method and application of astaxanthin-containing health food |
| CN105394749B (en) * | 2015-10-23 | 2018-03-20 | 武汉龙族药号生物医药科技有限公司 | A kind of Ricipe for health care food and preparation method and application containing astaxanthin |
| CN106722434A (en) * | 2015-11-19 | 2017-05-31 | 徐州统食品工业有限公司 | A kind of anti-oxidation functional food |
| CN105454733A (en) * | 2015-12-31 | 2016-04-06 | 中国科学院海洋研究所 | Rainbow trout nutrition enhancer and application thereof |
| CN106721918A (en) * | 2016-11-24 | 2017-05-31 | 云南民族大学 | Astaxanthin green tea oral tablet |
| CN107441236A (en) * | 2017-06-02 | 2017-12-08 | 杭州鑫伟低碳技术研发有限公司 | A kind of Astaxanthin In Haematococcus Pluvialis liver protecting product and preparation method thereof |
| CN108902958A (en) * | 2018-07-20 | 2018-11-30 | 深圳市博奥生物科技有限公司 | A kind of astaxanthin soft capsule and preparation method thereof |
| CN109430833A (en) * | 2018-10-31 | 2019-03-08 | 杭州鑫伟低碳技术研发有限公司 | A kind of composition and its application for improving reproduction cell vigor |
| CN110754659A (en) * | 2019-11-12 | 2020-02-07 | 青岛浩然海洋科技有限公司 | Production method of astaxanthin oral liquid |
| CN110839881A (en) * | 2019-11-26 | 2020-02-28 | 康道生物（南通）有限公司 | Ganoderma lucidum spore oil lycopene soft capsule and preparation process thereof |
| CN111363658A (en) * | 2020-03-05 | 2020-07-03 | 何凤霞 | A beverage containing Haematococcus pluvialis extract (astaxanthin) and its preparation method |
| CN112890133A (en) * | 2021-03-24 | 2021-06-04 | 康道生物（南通）有限公司 | Preparation process of haematococcus pluvialis capsules |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104770740A (en) | Haematococcus pluvialis and astaxanthin compound preparation | |
| Nagarajan et al. | Sustainable aquaculture and animal feed from microalgae–nutritive value and techno-functional components | |
| Seyidoglu et al. | A prominent superfood: Spirulina platensis | |
| Sarlin et al. | Efficacy of marine yeasts and baker's yeast as immunostimulants in Fenneropenaeus indicus: a comparative study | |
| Wu et al. | Bioactive substances and potentiality of marine microalgae | |
| Niu et al. | Dietary values of macroalgae Porphyra haitanensis in Litopenaeus vannamei under normal rearing and WSSV challenge conditions: Effect on growth, immune response and intestinal microbiota | |
| CN103564204B (en) | Shelling interphase crawfish feed and preparation method thereof | |
| JP2009517482A (en) | Nutritional supplement composition of algae and algae extract | |
| Basheer et al. | Microalgae in human health and medicine | |
| Sanjeewa et al. | Edible brown seaweeds: a review | |
| CN104886707A (en) | Composite solid meal replacement health-preservation anti-cancer fruit and vegetable beverage and preparation method thereof | |
| CN104664527A (en) | Composition with effects of preventing and resisting cancer, resisting radiation and eliminating heavy metals in bodies | |
| CN103918966A (en) | Composition containing Haematococcus pluvialis | |
| KR20140091674A (en) | Use of foti to enhance stem cell mobilization and proliferation | |
| CN104187679A (en) | Haematococcus pluvialis maca health product and preparation method thereof | |
| Harikrishnan et al. | Changes in immune genes expression, immune response, digestive enzymes-antioxidant status, and growth of catla (Catla catla) fed with Astragalus polysaccharides against edwardsiellosis disease | |
| CN106074317A (en) | Blue berry lipstick and preparation method thereof | |
| CN101715986A (en) | Preparation method and application of rich selenium haematococcus powder | |
| CN102793184A (en) | Compound antioxidant nutrition supplement and processing method thereof | |
| CN104336620A (en) | Compound nutritional vital wheat gluten and preparation method thereof | |
| CN104621409A (en) | Special additive for pseudosciaena crocea bait | |
| Kim et al. | Effects of dietary supplementation of fermented garlic powder on immune responses, blood components, and disease resistance against principal fish disease of juvenile olive flounder, Paralichthys olivaceus in low temperature season | |
| CN106923064A (en) | One kind fattens mandarin fish feed | |
| CN104799298A (en) | Nutrition supplementing liquid combining astaxanthin and omega 3 | |
| Kalkal et al. | Advances in control strategies and vaccine development of coccidiosis in poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150715 |